


# **“Shifting Gears” Towards Palliative Therapy for Recurrent Breast Cancer**

**Mohammad Jahanzeb, MD, FACP**


**Van Vleet Endowed Professor of Medical Oncology  
Chief, Division of Hematology-Oncology  
University of Tennessee Cancer Institute**

# Diminishing Response rates in Subsequent Lines of Therapy



# The interrelationship of therapies with curative and palliative intent

**Curative / life-prolonging therapy**



**Presentation**


**Death**



**Relieve suffering (palliative care)**

# Comprehensive cancer care

Anti-neoplastic Therapy





# Shifting Emphasis of Care

## DURING ANTITUMOR TREATMENT:

- Cure of disease
- Avoidance of premature death
- Maintenance or improvement in function
- Prolongation of life

## AFTER STOPPING ANTITUMOR TREATMENT:

- Relief of suffering
- Quality of life
- Staying in control
- A comfortable death
- Support for families and loved ones



National  
Comprehensive  
Cancer  
Network®

SCREENING<sup>a,b</sup>

- Uncontrolled symptoms or
- Moderate to severe distress related to cancer diagnosis and/or cancer therapy or
- Serious comorbid physical and psychosocial conditions or
- Life expectancy  $\leq 12$  mo
  - Potential indicators include:
    - ✦ Poor performance status ECOG  $\geq 3$  or KPS  $\leq 50$
    - ✦ Hypercalcemia
    - ✦ Brain or cerebrospinal fluid metastasis
    - ✦ Superior vena cava syndrome
    - ✦ Spinal cord compression
    - ✦ Cachexia
    - ✦ Malignant effusions
    - ✦ Bilirubin  $\geq 2.5$
    - ✦ Creatinine  $\geq 3$
- or
- Patient/family concerns about course of disease and decision-making or

Present

Not present

Rescreen at  
next visit

## ASSESSMENT

- Benefits/risks of anticancer therapy
- Symptoms
- Psychosocial or spiritual distress

[See PAL-4](#)

- Personal goals/expectations
- Educational and informational needs
- Cultural factors affecting

[See PAL-5](#)

Criteria for early consultation with palliative care specialist

[See PAL-6](#)

<sup>a</sup>Management of any patient with positive screening requires a care plan developed by a interdisciplinary team of physicians, nurses, mental health professionals, and chaplains.

<sup>b</sup>Oncologists should integrate palliative care into general oncology care for patients who meet screening criteria. Consultation/collaboration with a palliative care specialist/hospice team is recommended for patients with more complex issues.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

# **5 steps for successful advance care planning**

- 1. Introduce the topic**
- 2. Engage in structured discussions**
- 3. Document patient preferences**
- 4. Review, update**
- 5. Apply directives when need arises**

# Breaking Bad News

## Definition:

**Bad news is any news that seriously  
And adversely affects the patient's  
View of his or her future**

# Breaking Bad News

- S** Getting the SETTING right,
- P** What the patient PERCEIVES,
- I** An INVITATION to share the news,
- K** Giving the KNOWLEDGE.
- E** EMPATHISING & EXPLORING  
the patient's emotions, and
- S** STRATEGY and SUMMARY.

# Breaking Bad News

## The Empathic Response

1. Identify the emotion (theirs or yours)
2. Identify the source of the emotion
3. Respond in a way that shows you have made that connection

You don't have to agree with the viewpoint

You don't have to feel the emotion yourself

# Palliative Care: Expanding the Options

- Interdisciplinary care
- Symptom control
- Supportive care

## PALLIATIVE CARE ASSESSMENT

Benefits/risks of  
anticancer therapy

- Natural history of specific tumor
- Potential for response to further treatment
- Meaning of anticancer therapy to patient and family
- Impairment of vital organs
- Performance status

[Interventions \(See PAL-7\)](#)

Symptoms

- Pain → [Pain interventions \(See PAL-8\)](#)
- Dyspnea → [Dyspnea \(See PAL-9\)](#)
- Anorexia/cachexia → [Anorexia/cachexia interventions \(See PAL-11\)](#)
- Nausea/Vomiting → [Nausea/Vomiting \(See PAL-13\)](#)
- Constipation → [Constipation \(See PAL-15\)](#)
- Malignant bowel obstruction → [Malignant Bowel Obstruction \(See PAL-16\)](#)
- Fatigue/weakness/asthenia → [See NCCN Cancer-Related Fatigue Guidelines](#)
- Insomnia
- Sedation
- Delirium → [Delirium \(See PAL-18\)](#)

Psychosocial distress


- Psychosocial/psychiatric
- Spiritual or existential crisis → [See NCCN Distress Management Guidelines](#)
- Social support problems
  - Family
  - Community
- Resources problems
  - Financial

[Social Support/Resource Management \(See PAL-20\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.





Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

# **Approach to Palliative Care**

- **Principles of symptom management**

  - Understand the pathophysiology**

  - Manage quickly; continuous & breakthrough dosing**

  - Rationalize multisymptom management**

- **Coordination of care**

  - Patient, family education**

  - Interdisciplinary team**

- **Intended versus unintended effects**

  - Terminal sedation requires consultation**

# The EPEC-O<sup>TM</sup>

## Education in Palliative and End-of-life Care - Oncology Project

Emanuel LL, Ferris FD, von Gunten CF, Von Roenn J.

EPEC-O: Education in Palliative and End-of-life Care - Oncology.

© The EPEC<sup>TM</sup> Project, Chicago, IL, 2005

NorthWestren University

Feinberg School of Medicine

Chicago, Illinois

USA


The EPEC-O Curriculum is produced by the EPEC<sup>TM</sup> Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.

# **Common Symptoms in Terminal Cancer**

- **Pain**
- **Anorexia/Cachexia**
- **Fatigue**
- **Dyspnea**
- **Constipation**
- **Bowel Obstruction**
- **Anxiety/Depression**

# Selected Common Symptoms

- Pain
- Anorexia
- Fatigue
- Depression



[See Special Palliative Care Interventions: Imminently Dying Patient \(PAL-28\)](#)

[See List of Symptoms in Palliative Care Table of Contents](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

# **Pain Pathophysiology**

- **Acute pain**

**Identified event, resolves days–weeks**

**Usually nociceptive**

- **Chronic pain**

**Cause often not easily identified,  
multifactorial**

**Indeterminate duration**

**Nociceptive and / or neuropathic**

# Nociceptive pain

- Direct stimulation of intact nociceptors
- Transmission along normal nerves

**Somatic**

Easy to describe, localize

**Visceral**

Difficult to describe, localize



# Neuropathic pain

- **Disordered peripheral or central nerves**
- **Compression, transection, infiltration, ischemia, metabolic injury**
- **Varied types**
  - Peripheral, deafferentation, complex regional syndromes**

# WHO 3-step Ladder

**1 mild**

---

ASA

Acetaminophen

NSAID's

± *Adjuvants*

**2 moderate**

---

A/Codeine

A/Hydrocodone

A/Oxycodone

A/Dihydrocodeine

Tramadol

± *Adjuvants*

**3 severe**

---

Morphine

Hydromorphone

Methadone

Levorphanol

Fentanyl

Oxycodone

± *Adjuvants*

WHO Geneva, 1996.

# **Non-pharmacological pain management . . .**

- **Neurostimulation**  
TENS, acupuncture
- **Anesthesiological**  
Nerve block
- **Surgical**  
Cordotomy
- **Physical therapy**  
Exercise, heat, cold

# **Non-pharmacological pain management**

- **Psychological approaches**

  - Cognitive therapies**

  - (relaxation, imagery, hypnosis)**

  - Biofeedback**

  - Behavior therapy, psychotherapy**


- **Complementary therapies**

  - Massage**

  - Art, music, aroma therapy**

# Placebos

- **No role for placebos to assess or treat pain!**



# Nociceptive pain

- Tissue injury apparent
- Management

Opioids

Adjuvant / coanalgesics

# Neuropathic pain

- Pain may exceed observable injury
- Described as burning, tingling, shooting, stabbing, electrical
- Management
  - Opioids
  - Adjuvant / coanalgesics often required



# Pain management

- Don't delay for investigations or disease treatment
- Unmanaged pain => nervous system changes


Permanent damage  
amplify pain

- Treat underlying cause (eg, radiation for a neoplasm)

# Anorexia and Cachexia

## Cachexia – wasting syndrome

- ↓ Lean tissue
- ↓ Performance status
- Altered resting energy expenditure
- ↓ Appetite




[See Special Palliative Care Interventions:  
Imminently Dying Patient \(PAL-28\)](#)

[See List of Symptoms in  
Palliative Care Table of Contents](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## ANOREXIA/CACHEXIA



**See Special Palliative Care Interventions:  
Imminently Dying Patient (PAL-28)**

[See List of Symptoms in Palliative Care Table of Contents](#)

Note: All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

# Anorexia/Cachexia: Pathophysiology

- Chronic inflammation
- Metabolic changes
- Lipolytic / proteolytic substances
- Hormonal changes
- Role of neurotransmitters
- Cytokine impact on hypothalamus

Todorov P, et al. *Nature*, 1996.  
Todorov P, et al. *Cancer Research*, 1998.  
Zigman JM, et al. *Endocrinology*, 2003.  
Balkwill F, et al. *Lancet*, 2001.

# **Anorexia/Cachexia: Assessment**

- **Appetite / weight loss history**
- **Identify reversible causes**
- **Physical signs of wasting**
- **Biochemical markers**
- **Radiographic studies as indicated**

# Management of Anorexia

- Dexamethasone
- Megestrol acetate
- Tetrahydrocannabinol (THC)
- Androgens

Loprinzi CL, et al. *JCO*, 1999.

VonRoenn JH, et al. 2003.

Moertel CG, et al. *Cancer*, 1974.



# Management of Cachexia

- Investigational

Anabolic steroids

Omega-3-fatty acids

Amino acids

NSAIDs

Multi-vitamins

Exercise

Von Roenn JH, et al. *ASCO*, 2003.

Jatoi A, et al. *ASCO*, 2003.

Fearon KCH, et al. *Gut*, 2003.

McMillan DC, et al. *Br J Ca*, 1999.



# Fatigue

## Definition

- Persistent sense of tiredness
- Interferes with function
- Unrelieved by rest

# Fatigue

## Epidemiology

- High prevalence-varies with stage and primary
- High impact
- Patterns of fatigue

Chemotherapy

Radiotherapy

Volgelzang N, Breitbart W, et al. *Semin Hematal*, 1997.

Cella D, Peterman A. *Oncology*, 1998.

Stone P, Richardson A, et al. *Ann Oncol*, 2000.

Schwartz AL, Nail LM, et al. *Cancer Invest*, 2000.

# **Fatigue: Pathophysiology**

- **Multifactorial**
- **Abnormal energy metabolism**
- **Increased cytokine production**
- **Contributing factors**
  - Depression**
  - Sleep disorders**
  - Muscular dysfunction**

# Fatigue: Assessment

- Subjective; 0-10 rating scale
  - 4-6 = moderate fatigue
  - 7-10 = severe fatigue
- Fatigue history
- Current medications
- Associated symptoms/Comorbidities
- Malnutrition / Deconditioning

# Fatigue: Management

## Treatable etiologies

- Anemia
- Depression
- Pain
- Hypothyroidism
- Hypogonadism

# Fatigue: Management

## Non-pharmacologic therapies...

- Educate – patterns of fatigue
- Clarify role of underlying illness, treatment
- Optimize fluid, electrolyte intake, nutrition
- Physical activity/Energy conservation
- Involve other disciplines

# Fatigue: Pharmacologic Management

- Methylphenidate
- Dexamethasone, prednisone
- Modafinil

Bruera E. *Cancer Treatment Rep*, 1985.

Bruera E, et al. *JCO*, 2004.

Rammohan KW, et al. *J Neurol Neurosurg Psychiatry*, 2002.

# Depression

- Depressed mood
- Anhedonia – loss of interest or pleasure
- > 2 weeks
- Prevalence: up to 58% of cancer patients
- Untreated, associated with poor prognosis
- Knowledge of true extent of disease and prognosis do not lead to depression or adverse outcomes



# Symptoms of Depression-1

- Irritability
- Changes in
  - Appetite or weight
  - Sleep
  - Psychomotor activity
- Decreased energy
- Worthlessness, helplessness, hopelessness
- Guilt

# Symptoms of Depression-2

- **Difficulty thinking, concentrating, making decisions**
- **Suicidal ideation or wishes to hasten death**
- **Somatic symptoms often not helpful in this population**

# **Depresssion: Risk Factors-1**

- **Poorly controlled pain**
- **Progressive physical impairment**
- **Advanced disease**
- **Medications**

**Steroids**

**Chemotherapeutics**

# Depresssion: Risk Factors-2

- Particular diseases

Pancreatic, breast, lung, mets to nervous system

- Younger age

- Spiritual pain

- Risk factors in general population

Prior Hx, family Hx, social stress

Suicide attempts, substance use

# Depression: Pathophysiology

- **Involved neurotransmitters**

Norepinephrine

Serotonin

Dopamine

- **Genetics**

- **Environmental influences**

# **Depression: Assessment**

- **Assess for signs and symptoms noted above**

**Do you feel depressed most of the time?**

- **Family observations**
- **Screening tools**

# Depression: Assessment

- Differentiate between
  - Grief reactions
  - Adjustment disorders
  - Delirium, particularly hypoactive
  - Dementia
- Consult with mental health professionals

# Depression: Management

- **Counseling**
- **Complementary therapies**
- **Pharmacotherapy**
- **Combinations are best**
- **Lack of improvement within weeks suggests more aggressive therapy or psychiatry consult needed**



# Complementary therapies

- Relaxation
- Distraction
- Guided imagery
- Meditation
- Massage therapy
- Aromatherapy
- Self-hypnosis
- Exercise
- Sunlight

# Depression: Pharmacotherapy


- Tricyclic antidepressants
- SSRIs

Preferred as less adverse effects

- Psychostimulants
- Other antidepressants

# **Depression: Pharmacotherapy**

- **Choose by time to effect**
  - Days – psychostimulants**
  - Weeks / months – SSRIs, other antidepressants**
- **Start dosing low, titrate slowly**
- **Consider consultation**



Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Back to Palliative Care  
Table of Contents](#)

# Summary and Conclusions

- Need to 'shift gears' when tumor is no longer the target
- There is a systematic way to break bad news to the patient
- Most symptoms of terminal cancer are manageable
- NCCN palliative and supportive care guidelines are a useful and accessible tool for the practitioner